{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:32:47Z","timestamp":1785396767888,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00428-025-04337-6","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T20:25:45Z","timestamp":1764447945000},"page":"1283-1291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports"],"prefix":"10.1007","volume":"488","author":[{"given":"Vincent D.","family":"de Jager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"van der Ree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzabel Cajiao","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9on C.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"3","key":"4337_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4337_CR2","doi-asserted-by":"publisher","first-page":"100838","DOI":"10.1016\/j.lanepe.2024.100838","volume":"38","author":"VD de Jager","year":"2024","unstructured":"de Jager VD, Timens W, Bayle A et al (2024) Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. Lancet Reg Health Eur 38:100838","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"4337_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J et al (2023) Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34(4):339\u2013357","journal-title":"Ann Oncol"},{"issue":"1","key":"4337_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2022","unstructured":"Melosky B, Kambartel K, Hantschel M et al (2022) Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther 26(1):7\u201318","journal-title":"Mol Diagn Ther"},{"key":"4337_CR5","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.lanepe.2024.100839","volume":"38","author":"VD de Jager","year":"2024","unstructured":"de Jager VD, Timens W, Bayle A et al (2024) Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. Lancet Reg Health Eur 38:100839","journal-title":"Lancet Reg Health Eur"},{"key":"4337_CR6","doi-asserted-by":"publisher","first-page":"114125","DOI":"10.1016\/j.ejca.2024.114125","volume":"205","author":"VD de Jager","year":"2024","unstructured":"de Jager VD, Cajiao Garcia BN, Kuijpers C et al (2024) Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands. Eur J Cancer 205:114125","journal-title":"Eur J Cancer"},{"key":"4337_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2022.03.015","volume":"167","author":"BNC Garcia","year":"2022","unstructured":"Garcia BNC, van Kempen LC, Kuijpers C, Schuuring E, Willems SM, van der Wekken AJ (2022) Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study. Lung Cancer 167:1\u20137","journal-title":"Lung Cancer"},{"key":"4337_CR8","doi-asserted-by":"publisher","first-page":"100592","DOI":"10.1016\/j.lanepe.2023.100592","volume":"27","author":"RGP Gijtenbeek","year":"2023","unstructured":"Gijtenbeek RGP, Damhuis RAM, van der Wekken AJ, Hendriks LEL, Groen HJM, van Geffen WH (2023) Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study. Lancet Reg Health Eur 27:100592","journal-title":"Lancet Reg Health Eur"},{"key":"4337_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143641","author":"B Koopman","year":"2021","unstructured":"Koopman B, Cajiao Garcia BN, Kuijpers C et al (2021) A nationwide study on the impact of routine testing for EGFR mutations in advanced NSCLC reveals distinct survival patterns based on EGFR mutation subclasses. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13143641","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4337_CR10","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s10489-021-02635-5","volume":"52","author":"K Takahashi","year":"2022","unstructured":"Takahashi K, Yamamoto K, Kuchiba A, Koyama T (2022) Confidence interval for micro-averaged F (1) and macro-averaged F (1) scores. Appl Intell (Dordr) 52(5):4961\u20134972","journal-title":"Appl Intell (Dordr)"},{"key":"4337_CR11","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","volume":"368","author":"RD Riley","year":"2020","unstructured":"Riley RD, Ensor J, Snell KIE et al (2020) Calculating the sample size required for developing a clinical prediction model. BMJ 368:m441","journal-title":"BMJ"},{"issue":"1","key":"4337_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13073-024-01421-5","volume":"16","author":"RK Hart","year":"2024","unstructured":"Hart RK, Fokkema I, DiStefano M et al (2024) HGVS nomenclature 2024: improvements to community engagement, usability, and computability. Genome Med 16(1):149","journal-title":"Genome Med"},{"key":"4337_CR13","unstructured":"Kuijpers CCHJ, van den Heuvel MM, Overbeek LIH, van Slooten HJ, van Lindert ASR, Damhuis RAM, Willems SM. Landelijke variatie in moleculaire diagnostiek bij gemetastaseerde longkanker [National variation in molecular diagnostics in metastatic lung cancer]. Ned Tijdschr Geneeskd. 2018 Dec 5;162:D1607. Dutch."},{"key":"4337_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/jpi.jpi_52_21","volume":"13","author":"J Levy","year":"2022","unstructured":"Levy J, Vattikonda N, Haudenschild C, Christensen B, Vaickus L (2022) Comparison of machine-learning algorithms for the prediction of Current Procedural Terminology (CPT) codes from pathology reports. J Pathol Inform 13:3","journal-title":"J Pathol Inform"},{"key":"4337_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2022.100154","volume":"13","author":"H Lam","year":"2022","unstructured":"Lam H, Nguyen F, Wang X et al (2022) An accessible, efficient, and accurate natural language processing method for extracting diagnostic data from pathology reports. J Pathol Inform 13:100154","journal-title":"J Pathol Inform"},{"key":"4337_CR16","doi-asserted-by":"publisher","first-page":"6157861","DOI":"10.1155\/2022\/6157861","volume":"2022","author":"OJ Achilonu","year":"2022","unstructured":"Achilonu OJ, Singh E, Nimako G, Eijkemans R, Musenge E (2022) Rule-based information extraction from free-text pathology reports reveals trends in South African female breast cancer molecular subtypes and Ki67 expression. Biomed Res Int 2022:6157861","journal-title":"Biomed Res Int"},{"issue":"1","key":"4337_CR17","doi-asserted-by":"publisher","first-page":"23823","DOI":"10.1038\/s41598-021-03204-z","volume":"11","author":"GM Zaccaria","year":"2021","unstructured":"Zaccaria GM, Colella V, Colucci S et al (2021) Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology. Sci Rep 11(1):23823","journal-title":"Sci Rep"},{"issue":"12","key":"4337_CR18","doi-asserted-by":"publisher","first-page":"e18526","DOI":"10.2196\/18526","volume":"22","author":"B Ryu","year":"2020","unstructured":"Ryu B, Yoon E, Kim S et al (2020) Transformation of pathology reports into the common data model with oncology module: use case for colon cancer. J Med Internet Res 22(12):e18526","journal-title":"J Med Internet Res"},{"key":"4337_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00008","volume":"3","author":"T Oliwa","year":"2019","unstructured":"Oliwa T, Maron SB, Chase LM et al (2019) Obtaining knowledge in pathology reports through a natural language processing approach with classification, named-entity recognition, and relation-extraction heuristics. JCO Clin Cancer Inform 3:1\u20138","journal-title":"JCO Clin Cancer Inform"},{"key":"4337_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijmedinf.2019.01.004","volume":"124","author":"L Chen","year":"2019","unstructured":"Chen L, Song L, Shao Y, Li D, Ding K (2019) Using natural language processing to extract clinically useful information from Chinese electronic medical records. Int J Med Inform 124:6\u201312","journal-title":"Int J Med Inform"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04337-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04337-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04337-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:54:22Z","timestamp":1781344462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04337-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4337"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04337-6","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the privacy and scientific committee of Palga and the ethical committee of the Netherlands Comprehensive Cancer Organization (24\u201300395). Informed consent was not required due to the study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"VdJ has received speaker fees received from Uitgeverij Jaap (Roche Diagnostics Netherlands B.V., Janssen-Cilag B.V.) (paid to UMCG account) and Canadian Anatomic and Molecular Pathology \u2013 Pathology Oncology Digital Series (Amgen, Bayer, Daiichi-Sankyo, AstraZeneca, Eli Lilly, Roche, Pfizer) (paid to UMCG account).AvdW has received grants or contracts from AstraZeneca, Boehringer Ingelheim, Pfizer, Roche, and Takeda, has received consulting fees from AstraZeneca, Janssen, Eli Lilly, Roche, and Takeda, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, and Roche, has a leadership or fiduciary role in oncology section NVALT, guideline committee NSCLC and CUP, dure geneesmiddelen committee NVALT and FMS.LvK has received institutional grants or contracts from Amgen, AstraZeneca, Bayer, Janssen-Cilag, Merck, Roche, and Servier, has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and Roche (all to institution), has received support for attending meetings and\/or travel from Roche and ThermoFisher (all to institution), has participated on a Data Safety Monitoring Board or Advisory Board of Cyclomics, Janssen-Cilag, LOGEX, Merck, Menarini, Protyon, and Roche (all payments to institution), has a leadership or fiduciary role in the EORTC Melanoma Group and the Commission Personalized Medicine \u2013 Belgium (all payments to institution), has stock or stock options in Cyclomics (personal).ES has received (unrestricted) grants from Abbott, Biocartis, AstraZeneca, Invitae\/Archer, Bayer, Bio-Rad, Roche, Agena Bioscience, CC Diagnositcs, MSD\/Merck, and SNN\/EFRO (all paid to UMCG institution), has received advisory board (incidental) and travel expenses (honoraria\/grant paid to UMCG institution) from MSD\/Merck, AstraZeneca, Roche, Novartis, Bayer, BMS, Lilly, Amgen, Illumina, Agena Bioscience, CC Diagnostics, and Janssen Cilag (Johnson&Johnson), has received advisory board (incidental) (honoraria\/grant paid to UMCG institution) from Astellas Pharma, GSK, Sinnovisionlab, Sysmex, and Protyon, has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Bio-Rad (travel expenses and honoraria paid to UMCG institution), Seracare (honoraria paid to UMCG institution), Roche (travel expenses and honoraria paid to UMCG institution), Biocartis (travel expenses and honoraria paid to UMCG institution), Lilly (travel expenses and honoraria paid to UMCG institution), Agena Bioscience (travel expenses and honoraria paid to UMCG institution), and Illumina (honoraria paid to UMCG institution, has received support for attending meetings and\/or travel from BioRad (only travel expenses), Biocartis (only travel expenses), Ageno Sciences (only travel expenses), Illumina (travel expenses), Roche\/Foundation Medicine (travel\/hotel\/registration expenses (partially)), and QCMD (travel\/hotel\/registration expenses), has a leadership or fiduciary role in the Dutch Society of Pathology (board member, unpaid), European Society of Pathology (board member, unpaid), European Liquid Biopsy Society (board member, unpaid), is chairman\/member of the Committee for assessment of molecular diagnostics (cieBOD, honoraria paid to UMCG institution), is committee member of the National guideline advisory committee (honoraria paid to UMCG institution), and is board member of the Committee for Clinical Essential Targets (cieKNT) (unpaid).SW has received grants or contracts from Roche, Bayer, Eli Lilly, Pfizer, AstraZeneca, Merck Sharp & Dohme, Amgen, and Novartis (unrestricted research grants), and has a leadership or fiduciary role in the strategic advisory board of Roche. Dr. Garcia declares no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}